 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19827 News |  |
| 12345678910111213...203204» |
- | Remicade (infliximab) / J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal: INTESTINAL ULTRASOUND AND ITS ROLE IN THE ACUTE SETTING: STENOSING CROHN'S DISEASE AND ACUTE BOWEL OBSTRUCTION DUE TO FOREIGN BODY INGESTION (DENTAL POST AND CROWN). (Pubmed Central) - Sep 5, 2024
Even though an initial course of intraneous steroids is ordered, due to previous medical history of a persistent active Crohn's disease with loss of response to three advanced therapies, as well as the very low probability of progression of the foreign body along with the risk of permanent impaction or perforation, surgery is indicated. Ileocecal resection with extraction of the foreign body is performed uneventfully.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal, Combination therapy: 6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy. (Pubmed Central) - Sep 5, 2024
6-TGN levels were weakly associated with infliximab but not adalimumab levels in combination therapy. 6-TGN levels in the lower end of the therapeutic range (230-260 pmol/8
- | Humira (adalimumab) / AbbVie
Preclinical, Journal: Can adalimumab prevent from acute effects of lipopolysaccharide induced renal injury in rats? (Pubmed Central) - Sep 4, 2024
Because of its anti-inflammatory property, adalimumab pretreatment may have protective effects on experimental kidney injury. Adalimumab could be considered as a protective agent to acute effects of lipopolysaccharide induced renal injury.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study. (Pubmed Central) - Sep 4, 2024
PASI was higher after compared to before dose escalation for etanercept (p?=?0.036), but not for adalimumab (p?=?0.832) or ustekinumab (p?=?0.300). Dose escalation was comparatively more frequent with ustekinumab than with adalimumab or etanercept; however, treatment discontinuation after dose escalation was more common with adalimumab and etanercept than ustekinumab.
- | Humira (adalimumab) / AbbVie
Journal: A Neglected Disease: Hidradenitis Suppurativa a Rare Cause of Amyloidosis Complicated With Sepsis and Renal Failure: A Case Report. (Pubmed Central) - Sep 4, 2024
After 15 days of hospitalization, his sepsis was treated, but he was taken to a routine hemodialysis programme. In the presence of amyloidosis with intervenient infections, the risk of chronic renal failure in HS cases can be kept in mind even if the patient is receiving TNF inhibitors.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Reply. (Pubmed Central) - Sep 3, 2024
In the presence of amyloidosis with intervenient infections, the risk of chronic renal failure in HS cases can be kept in mind even if the patient is receiving TNF inhibitors. No abstract available
- | Humira (adalimumab) / AbbVie
Journal: SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis. (Pubmed Central) - Sep 2, 2024
P3
Conversely, during maintenance up to week 52, increasing the concentration via dose translated to better responses more robustly. The ER findings for SERENE UC were consistent with SERENE CD.
- | Humira (adalimumab) / AbbVie
Journal: SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease. (Pubmed Central) - Sep 2, 2024
P3
In the induction study, patients with lower effective adalimumab clearance responded better, whereas in the maintenance study average concentration drove primary efficacy end points at Week 56. Research extending these findings to other indications is needed.
- || Review, Journal: Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review. (Pubmed Central) - Sep 1, 2024
Due to the potential significant impairment in quality of life caused by pouchitis, it is essential to address the gaps in knowledge for both patients and physicians in its treatment. Therefore, well-designed and adequately powered studies should assess the optimal treatment for pouchitis.
- | Simponi (golimumab) / J&J
Journal: Intravenous Golimumab in the Treatment of Juvenile Idiopathic Arthritis and Its Associated Uveitis. (Pubmed Central) - Sep 1, 2024
Intravenous golimumab proves to be efficacious and safe for inducing and sustaining remission in JIA and JIA-associated uveitis. Nonetheless, further robust studies with larger sample sizes are needed to substantiate our findings.
- | Humira (adalimumab) / AbbVie
Journal: Adalimumab-Associated Depressive Symptoms in a Patient With Vasculitis, Autoinflammation, Immunodeficiency, and Hematologic Defects Syndrome. (Pubmed Central) - Sep 1, 2024
Nonetheless, further robust studies with larger sample sizes are needed to substantiate our findings. No abstract available
- || Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review. (Pubmed Central) - Sep 1, 2024
agent, as reported by 2 studies...Safety was comparable across therapies. Future studies should explore the literature gaps identified, including limited comparative studies with small sample sizes, variations in study designs and patient characteristics, varied definitions of CR, and limited use of patient-reported outcome measures in real-world settings.
- | Retrospective data, Journal: Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study. (Pubmed Central) - Aug 31, 2024
AS patients on their first anti-TNF treatment for at least two years demonstrated a favorable long-term treatment retention rate, with a 24.0% discontinuation rate over a 10.6-year overall survival period. The predictors for discontinuation varied by causes, underscoring the complexity of treatment response and the importance of personalized approaches to treatment management.
- || Clinical, Retrospective data, Review, Journal: Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis. (Pubmed Central) - Aug 31, 2024
The predictors for discontinuation varied by causes, underscoring the complexity of treatment response and the importance of personalized approaches to treatment management. Tocilizumab and rituximab have better efficacy and safety in the treatment of D2T RA, and the 8
- | Humira (adalimumab) / AbbVie
Journal: Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor, successfully treated with adalimumab. (Pubmed Central) - Aug 28, 2024
Tocilizumab and rituximab have better efficacy and safety in the treatment of D2T RA, and the 8 No abstract available
- | Journal: Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposing. (Pubmed Central) - Aug 27, 2024
No abstract available The results of the present study can provide novel insights into the pathogenesis and treatment of RA and OP.
- | Humira (adalimumab) / AbbVie
Journal: Case 328: Brown Tumor in Hyperparathyroidism Due to Parathyroid Adenoma. (Pubmed Central) - Aug 27, 2024
inhibitor (adalimumab), which was effective for pain, the patient was lost to follow-up...Routine blood tests revealed a normal blood cell count, creatinine level of 0.64 mg/dL (56.58 ?mol/L) (normal range, 0.30-1.1 mg/dL [26.52-97.24 ?mol/L]), C-reactive protein level of 1.1 mg/dL (normal, <1 mg/dL), and vitamin D level of 21 ng/mL (52.42 nmol/L) (normal range, 30-100 ng/mL [74.88-249.60 nmol/L]). Noncontrast MRI of the thoracic and lumbar spine, MRI of the sacroiliac joints, and CT of the abdomen and pelvis were performed.
- | Humira (adalimumab) / AbbVie
Journal: Clinical Course of Bio Naive Ulcerative Colitis Patients Five Years After Initiation of Adalimumab in a Nationwide Cohort. (Pubmed Central) - Aug 27, 2024
Among bio-naive UC patients who were started on ADA, a third were still on the drug at the end of 5 years and half had endoscopic remission. The rate of discontinuation was highest within the first year of initiation, but patients continued to stop the drug over the course of follow-up.
- | Humira (adalimumab) / AbbVie
Journal: Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets. (Pubmed Central) - Aug 27, 2024
The gut microbiota undergoes diverse changes according to the treatment response during ADA treatment. These changes provide insights into predicting treatment responses to ADA and offer new therapeutic targets for UC.
- | Humira (adalimumab) / AbbVie
Biomarker, Journal: Increased neutrophil extracellular trap formation in oligoarticular, polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis: biomarkers for diagnosis and disease activity. (Pubmed Central) - Aug 26, 2024
The ability of neutrophils to release NETs and the effect of adalimumab on NET formation was assessed via in vitro stimulation and inhibition studies...Circulating NET-derived products possess potential diagnostic and disease monitoring value. Furthermore, the preliminary results related to the molecular mechanisms of NET formation in JIA patients provide a theoretical basis for NET-targeted therapy.
- | Humira (adalimumab) / AbbVie
Journal: Treatment of facial and axillary lupus miliaris with adalimumab. (Pubmed Central) - Aug 26, 2024
Furthermore, the preliminary results related to the molecular mechanisms of NET formation in JIA patients provide a theoretical basis for NET-targeted therapy. No abstract available
- | Tremfya (guselkumab) / J&J
Journal, HEOR: Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis. (Pubmed Central) - Aug 23, 2024
No abstract available GUS-mediated improvements in anxiety, depression, and overall HRQoL are not solely mediated by resolution of PsO signs, suggesting GUS use has a potential direct effect on anxiety and depression.
- | Rinvoq (upadacitinib) / AbbVie
Journal: Clinical and Ultrasonographic Remission in Bio-na (Pubmed Central) - Aug 23, 2024
UPARAREMUS is the first study evaluating the efficacy of upadacitinib in reaching both clinical and US remission in patients with RA. At 24
- || Review, Journal: Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors (Pubmed Central) - Aug 23, 2024
Nevertheless, these therapies are expensive and are associated with potential adverse effects, including increased risk of infections and malignancies. This review discusses the mechanisms, clinical efficacy, safety profiles, and therapeutic positioning of anti-TNF agents in IBD management, integrating current Korean treatment guidelines.
- | Journal: Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease. (Pubmed Central) - Aug 22, 2024
There may be a significant delay in biologic treatment initiation in patients with IBD. The most important variables associated with this delay included self-identification as Black, longer distance from site, and lack of initial insurance coverage approval.
- | Humira (adalimumab) / AbbVie
Journal: HLA-DQA1*05 associates with anti-TNF immunogenicity and low adalimumab trough concentrations in inflammatory bowel disease patients from the SERENE UC and CD studies. (Pubmed Central) - Aug 20, 2024
This work extends previous results in Crohn's disease to ulcerative colitis and directly shows a genetic association in patients with low drug concentrations. This work builds on existing literature to suggest genetic screening as a useful tool for clinicians concerned with patient anti-TNF immunogenicity.
- | Humira (adalimumab) / AbbVie
Journal: Development of Postsurgical Pyoderma Gangrenosum with New Keloid after Keloid Resection. (Pubmed Central) - Aug 20, 2024
Corticosteroid taping may be the safest therapy for patients with a history of PG. Conversely, if there is suspicion that a patient is prone to keloid development, diagnostic biopsies and surgical management of PG ulcers should be avoided or conducted with care.
- || Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Review, Journal: Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review. (Pubmed Central) - Aug 19, 2024
PG recurred in 15.5% (11/71) of those reported the outcome. Our study suggests that biologic therapies may be an attractive therapeutic option for PG with an excellent efficacy.
- | Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Possible effectiveness of switching biologics from adalimumab to certolizumab pegol in pyoderma gangrenosum. (Pubmed Central) - Aug 19, 2024
Our study suggests that biologic therapies may be an attractive therapeutic option for PG with an excellent efficacy. No abstract available
- || Clinical, Journal: Drug Survival on First Biologic Therapy Among Late-Onset Rheumatoid Arthritis Patients Compared to Early-Onset Patients: A Population-Based Cohort Study. (Pubmed Central) - Aug 17, 2024
No abstract available Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups.
- || Review, Journal: Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. (Pubmed Central) - Aug 17, 2024
Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups. This systematic review provides robust evidence regarding treatment options for individuals with psoriasis and MD, emphasizing the potential benefits of specific drugs in managing both conditions concurrently.
- || Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Review, Journal: Pyodermatitis-pyostomatitis vegetans: a case report and systematic review focusing on oral involvement. (Pubmed Central) - Aug 17, 2024
There is no established therapeutic protocol for PSV and management primarily consists of topical and/or systemic corticosteroids, antirheumatic drugs (sulfasalazine, mesalazine), monoclonal antibody (infliximab, adalimumab) immunosuppressives (azathioprine, methotrexate), antibiotics (dapsone), or a combination of these. The risk of recurrence of oral lesions is considerable when the medication dose is decreased or fully interrupted.
- | Humira (adalimumab) / AbbVie
Journal: Comment on "Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open- Label, Prospective, Pilot Study". (Pubmed Central) - Aug 15, 2024
Methodological refinements, including a randomized controlled trial design with a larger sample size, extended follow-up, detailed adverse event data, standardized tapering protocols, and incorporation of objective outcome measures, are recommended to enhance the reliability and generalizability of the findings. These improvements could significantly inform clinical practice and contribute to the evidence base for pediatric uveitis management.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal, Epigenetic controller: Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease. (Pubmed Central) - Aug 14, 2024
These improvements could significantly inform clinical practice and contribute to the evidence base for pediatric uveitis management. Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy.
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Treatment Persistence Among Advanced Therapy-Na (Pubmed Central) - Aug 14, 2024
Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy. This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-na
- | Journal: Revealing patient characteristics and treatment outcomes in ultra-long biologic users for psoriasis. (Pubmed Central) - Aug 14, 2024
Remarkably, ultra-long use was reached also in patients having multiple comorbidities (including PsA) and a variety of dose adjustments of the biologics was applied. These results provide clinicians with important evidence on ultra-long biological treatment, thereby improving psoriasis care and management of treatment expectations.
- | Retrospective data, Journal, Real-world evidence, Real-world: Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network. (Pubmed Central) - Aug 13, 2024
Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA.
- || Review, Journal: Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. (Pubmed Central) - Aug 12, 2024
The choice of biologic agent should consider ISR risk. Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Supplemented Gegen Qinlian Decoction Formula attenuates podocyte mitochondrial fission and renal fibrosis in diabetic kidney disease by inhibiting TNF-?-mediated necroptosis, compared with empagliflozin. (Pubmed Central) - Aug 10, 2024
In the present study, we showed that H-SGQDF, similar to EMPA, attenuates podocyte mitochondrial fission and RF, and that the underlying therapeutic mechanisms are closely related to inhibiting the activation of the RIPK1/RIPK3/MLKL signaling axis in diabetic kidneys. Our findings provide new pharmacological evidence for the application of H-SGQDF in the RF treatment of DKD.
- || Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Review, Journal: Comparison of adalimumab with methotrexate for psoriasis: A meta-analysis of randomized controlled studies. (Pubmed Central) - Aug 9, 2024
Our findings provide new pharmacological evidence for the application of H-SGQDF in the RF treatment of DKD. Adalimumab was superior to methotrexate for the treatment of psoriasis.
- | Humira (adalimumab) / AbbVie
Journal, Patient reported outcomes: Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA. (Pubmed Central) - Aug 9, 2024
P3
Adalimumab was superior to methotrexate for the treatment of psoriasis. The VOLTAIRE-RA trial compared the efficacy and safety of an adalimumab biosimilar (Cyltezo
- | Humira (adalimumab) / AbbVie
Journal, Patient reported outcomes: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA. (Pubmed Central) - Aug 9, 2024
P3
The VOLTAIRE-RA trial compared the efficacy and safety of an adalimumab biosimilar (Cyltezo In patients with moderate to severely active RA, adalimumab-adbm and adalimumab reference product were both associated with clinically meaningful improvements in SF-36 PCS, MCS, and domain scores that were highly similar at weeks
- | Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. (Pubmed Central) - Aug 9, 2024
In patients with moderate to severely active RA, adalimumab-adbm and adalimumab reference product were both associated with clinically meaningful improvements in SF-36 PCS, MCS, and domain scores that were highly similar at weeks The most commonly used drugs at inclusion were Humira
- | Humira (adalimumab) / AbbVie
Journal: Nodal T-Follicular Helper Cell Lymphoma, Angioimmunoblastic-Type, Diagnosed in a Patient with Psoriasis Following COVID-19 Vaccination under Adalimumab Treatment: A Causal Association? (Pubmed Central) - Aug 9, 2024
We report a case of a patient with psoriasis under adalimumab developing nodal T-follicular helper cell lymphoma, angioimmunoblastic-type following the mRNA-1273 COVID-19 vaccine. We suspect that adalimumab, methotrexate, Epstein-Barr virus (EBV) reactivation, previous reactive lymphoid hyperplasia and psoriasis per se predispose our patient to a lymphoma-prone condition, and the two doses of the mRNA vaccine act as the last straw.
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Humira (adalimumab) / AbbVie
Journal: Severe Occlusive Retinal Vasculitis in an Immunocompetent Patient with Chronic CMV Anterior Uveitis. (Pubmed Central) - Aug 8, 2024
Thus far she has responded very well to treatment. This case highlights the importance of serial posterior segment examinations and HLA-B51 testing in individuals with cytomegalovirus anterior uveitis.
- | Humira (adalimumab) / AbbVie
Journal: Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases. (Pubmed Central) - Aug 8, 2024
Despite a reduction in sensitivity, our system demonstrated a concentration-dependent response to NO, successfully secreting functional nanobodies with binding affinities comparable to the commonly used drug Adalimumab, as confirmed by enzyme-linked immunosorbent assay and in vitro assays...Additionally, we provided a mathematical framework to assess critical parameters in engineering probiotic systems, including the production and diffusion of relevant molecules, bacterial colonization rates, and particle interactions. This integrated approach expands the synthetic biology toolbox for EcN-based therapies, providing novel parts, circuits, and a model for tunable responses at inflammatory hotspots.
- | Humira (adalimumab) / AbbVie
Journal: Adalimumab-induced leukocytoclastic vasculitis in a patient with ankylosing spondylitis: A case report. (Pubmed Central) - Aug 8, 2024
Discontinuation of adalimumab and treatment with high dose glucocorticoids and intravenous pulse of cyclophosphamide resulted in the resolution of her ischemic lesions. This case underscores the importance of considering drug-related side effects in patients with new skin lesions, particularly in the context of rheumatic diseases such as AS.
- | Humira (adalimumab) / AbbVie, Tremfya (guselkumab) / J&J
Biomarker, Journal: Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy. (Pubmed Central) - Aug 8, 2024
P3
inhibition in human blood and tissue over time with FDA-approved doses of guselkumab and ADA. Trial registration:ClinicalTrials.govClinicalTrials.gov (NCT02207231).
- | Humira (adalimumab) / AbbVie
Journal: Lichenoid Drug Eruption Secondary to Adalimumab: A Case Report. (Pubmed Central) - Aug 8, 2024
The discontinuation of adalimumab must be carefully weighed against its therapeutic benefits, as the discontinuation might trigger a severe form of inflammation in the primary autoimmune disease being treated. Extreme caution, early intervention, and a multidisciplinary approach are best for the overall well-being and optimal care of the individual.
- | Humira (adalimumab) / AbbVie
Journal: De novo manifestations during adalimumab treatment in Beh (Pubmed Central) - Aug 7, 2024
Of these, 57% were major organ involvement, mainly vascular involvement. None of the patients developed posterior uveitis.